This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neoplasm of uncertain or unknown behaviour of urinary organs비뇨기관의 행동양식 불명 또는 미상의 신생물

Contents and key points
ItemDetails
A. Classification codesICD-10: D41 (Neoplasm of uncertain or unknown behavior of urinary organs) | Special Copayment Reduction: V193 (cancer special copayment reduction: 5% copayment for 5 years from the registration date)
B. SynonymsUrothelial carcinoma in situ (urothelial CIS), papillary urothelial neoplasm of low malignant potential (PUNLMP), neoplasm of uncertain behavior of the renal pelvis and ureter (D41.1, D41.2), neoplasm of uncertain behavior of the kidney (D41.0)
C. Adult onsetPresents mainly in men in their 50s to 70s, with painless hematuria as the main symptom. Smoking and occupational aromatic amine exposure are the key risk factors.
1. HistoryThe bladder tumor grading system was established in the 1973 WHO classification, and the current low-grade/high-grade dichotomous system was established with the 2004 and 2016 revisions.
2. CausesSmoking is the strongest risk factor; aromatic amines (benzidine, β-naphthylamine), radiation, arsenic, and chronic bladder irritation are additional causes.
3. GeneticsCharacterized by dichotomous genetic abnormalities: FGFR3/HRAS mutations (low-grade papillary pathway) versus TP53/RB1 loss (high-grade flat pathway).
4. General epidemiologyBladder cancer is the 4th most common cancer in men worldwide; in Korea it also ranks high among cancers in men and occurs predominantly in older adults and smokers.
5. PathophysiologyFGFR3 activating mutations (papillary, low-grade) and TP53/RB1 inactivation (flat, high-grade) form the two main carcinogenic pathways.
6. SymptomsPainless hematuria (gross or microscopic) is most common, and urinary frequency, urgency, and dysuria may accompany it; with progression, flank pain and lower extremity edema occur.
7. SignsOn cystoscopy, papillary tumors or red velvety flat lesions are found, along with flank pain due to hydronephrosis and suprapubic bladder tenderness.
8. ScreeningUrine cytology and cystoscopy in high-risk groups are useful for early detection; screening of the general population is not currently recommended.
9. DiagnosisCystoscopy and TURBT, urine cytology, CT urography, fluorescence cystoscopy (HAL/PDD), and molecular markers (UroVysion FISH) are used.
10. TreatmentIntravesical BCG or chemotherapy instillation after TURBT; radical cystectomy is standard for high-risk non-muscle-invasive or muscle-invasive lesions.
11. PrognosisThe 5-year recurrence rate of low-grade papillary tumors is about 50%; in high-grade disease or CIS, the risk of progression to muscle-invasive disease is 20–30%, so long-term follow-up is essential.
12. PreventionSmoking cessation is the most effective prevention; avoiding occupational carcinogen exposure, increasing fluid intake, and regular urologic checkups are key preventive strategies.
13. ReferencesEAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) … and 9 other papers

1. History

The history of the classification of urinary organ tumors begins with systematic descriptions of bladder tumors in the late 19th century. In 1893 Billroth first described papillary neoplasms of the bladder surgically, and in the early 20th century Albarran and Imbert studied the relationship between the histologic features and clinical course of bladder tumors. In 1939 Jewett and Strong first proposed a staging classification of bladder cancer based on invasion of the muscle layer, providing a basis for treatment planning, which later became the foundation of the TNM staging system.

The grading system for urothelial tumors was first formalized in the 1973 World Health Organization (WHO) classification. In this classification, bladder tumors were classified as papilloma (grade 1), low-grade transitional cell carcinoma (grade 2), and high-grade transitional cell carcinoma (grade 3). However, this classification was criticized for low interobserver reproducibility, and in particular the problem was raised that the grade 2 category included a clinically very heterogeneous group. In 1998 the International Society of Urological Pathology (ISUP) revised the classification system for noninvasive urothelial tumors, which was reflected in the 2004 WHO classification. In this revision, noninvasive papillary urothelial tumors were classified as papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), low-grade noninvasive papillary urothelial carcinoma, and high-grade noninvasive papillary urothelial carcinoma.

PUNLMP (Papillary Urothelial Neoplasm of Low Malignant Potential) is a core component of the D41 code, and the concept was introduced to clarify a clinically uncertain entity lying between benign papilloma and low-grade carcinoma. The independent clinical significance of bladder carcinoma in situ (CIS) was first recognized by Melicow in 1952, and it was later shown that CIS, as a non-muscle-invasive high-grade lesion, is a major risk factor for progression to muscle-invasive cancer. The 2016 WHO classification (5th edition) revision integrated molecular profiling to further subdivide the pathophysiological features of tumors.

In Korea, the detection frequency of non-muscle-invasive bladder tumors has increased since the 1990s with the wider availability of cystoscopy and abdominal ultrasound. According to National Cancer Center data, bladder cancer remains in the top 5–6 by annual incidence among Korean men, and noninvasive low-grade lesions and tumors corresponding to the D41 code account for about 70–75% of all bladder tumors.


2. Causes

Smoking is the strongest risk factor for the development of urothelial tumors of the bladder and upper urinary tract. Smokers have about a 2–4 times higher risk of bladder cancer than nonsmokers, and the risk increases in proportion to smoking duration and amount. The key mechanism is that carcinogens in tobacco smoke (4-aminobiphenyl, acrolein, benzopyrene, etc.) are filtered by the kidneys and then concentrated in the bladder, causing repeated DNA damage to the urothelium. After smoking cessation, the risk gradually decreases but does not fully return to baseline.

Among occupational carcinogens, aromatic amine compounds are particularly important. Benzidine, β-naphthylamine, and 4-aminobiphenyl used in the rubber, dye, and printing industries have been identified as potent bladder carcinogens and have been banned in many countries. However, exposure risk still exists in developing countries. The risk is also increased among hairdressers, barbers, truck drivers, metalworkers, and aluminum smelter workers.

Arsenic is strongly associated with increased bladder cancer incidence in areas with contaminated well water (Taiwan, Bangladesh, Chile, Argentina, etc.), and groundwater arsenic contamination has also been reported in some regions of Korea. Radiation exposure increases the risk of secondary bladder neoplasms in patients who received pelvic radiation therapy (for cervical, rectal, prostate cancer, etc.). The alkylating agent cyclophosphamide is also known to increase the risk of hemorrhagic cystitis and bladder cancer. Chronic bladder irritation (chronic urinary tract infection, bladder stones, long-term indwelling catheter) is associated with the development of squamous cell carcinoma, and in particular schistosomiasis infection is a major cause of squamous-type bladder cancer in Africa.


3. Genetics

The most important genetic abnormalities in neoplasms of uncertain behavior of the urinary organs are divided into the low-grade papillary pathway and the high-grade flat pathway. In the low-grade papillary pathway, FGFR3 (fibroblast growth factor receptor 3) mutation is central. FGFR3 activating mutations are found in about 60–80% of noninvasive papillary bladder tumors and are especially common in PUNLMP and low-grade urothelial carcinoma. FGFR3 mutations are associated with a relatively stable clinical course and provide the rationale for targeted therapy with FGFR inhibitors.

HRAS activating mutations (codons 12, 13, 61) are also observed in about 10–15% of low-grade papillary tumors. PIK3CA (PI3K catalytic subunit alpha) mutations also occur in low-grade lesions and activate the AKT/mTOR pathway. In the high-grade flat pathway, TP53 mutation/loss is found in about 50–60% of bladder CIS and high-grade invasive cancers, and RB1 (retinoblastoma gene) loss is also commonly observed in high-grade lesions. Loss of the short arm of chromosome 9 (9p) is the most common early genetic abnormality in urothelial tumors, observed in both low and high grade, and includes the CDKN2A (encoding p16, p14ARF) gene.

In molecular subtype classification, urothelial bladder cancer is broadly divided into luminally enriched subtypes (rich in FGFR3 mutations) and basal/squamous subtypes (TP53 mutations, expression of basal cell markers), and this classification is also used to predict response to immunotherapy. Mutations in ERCC2 (a DNA excision repair gene) are associated with good response to cisplatin-based chemotherapy. In upper urinary tract urothelial tumors (renal pelvis, ureter), Lynch syndrome-associated MMR (mismatch repair) gene mutations are found in about 5–10%, so genetic counseling is needed.


4. General epidemiology

Bladder cancer is the 4th most common cancer in men and the 11th most common in women worldwide. The annual number of new bladder cancer cases worldwide is about 570,000 (as of 2020), and the number of bladder cancer-related deaths is about 210,000. By region, incidence is high in Southern Europe, North Africa, and North America and relatively low in Asia. The crude incidence of bladder cancer in Korea as of 2020 is about 12.4 per 100,000 men and about 3.0 per 100,000 women, ranking 7th–8th in cancer incidence among men.

By age, incidence increases sharply from the 60s onward, and the median age at onset is about 73 years. Incidence is about 3–4 times higher in men than in women, but women tend to be diagnosed at a more advanced stage, drawing attention to sex differences in prognosis. By race, the overall incidence of bladder cancer is higher in White than in Black people, but the proportion of muscle-invasive cancer is higher in Black patients.

Among noninvasive bladder tumors (Ta, Tis), lesions corresponding to the D41 code (PUNLMP, low-grade noninvasive tumors, CIS) account for about 70–75% of all bladder tumors. PUNLMP makes up about 1–4% of all bladder urothelial tumors, low-grade noninvasive papillary urothelial carcinoma about 50–55%, and bladder CIS about 10–15% of newly diagnosed bladder cancers. Upper urinary tract urothelial tumors (renal pelvis and ureter) account for about 5–10% of all urothelial tumors.


5. Pathophysiology

The pathogenesis of urothelial neoplasms of the urinary organs is currently best explained by the bifurcated pathway model of carcinogenesis. The two pathways form clinically different tumors through different genetic abnormalities.

Pathway 1 (papillary, low-grade pathway): Normal urothelium progresses stepwise through proliferative hyperplasia to papilloma, PUNLMP, and low-grade papillary urothelial tumors. FGFR3 mutation is the initial driver event, stimulating cell proliferation through activation of the RAS-MAPK pathway. Tumors in this pathway may be accompanied by TERT promoter mutations and PIK3CA mutations and show relatively low chromosomal instability and low mutation burden. Recurrence is frequent, but progression to muscle-invasive disease is less than about 5%, so the prognosis is relatively favorable.

Pathway 2 (flat, high-grade pathway): Normal urothelium progresses to high-grade invasive cancer via dysplasia and carcinoma in situ (CIS) without passing through hyperplasia. TP53 mutation/loss is the initial event, disabling the G1/S cell cycle checkpoint. RB1 loss, E2F transcription factor activation, and cyclin D1 overexpression accelerate cell cycle deregulation. Tumors in this pathway are characterized by high chromosomal instability, high TMB, and numerous somatic mutations, and because of high immunogenicity, their responsiveness to immunotherapy is relatively good.

In the carcinogenic process of urothelial cells, tobacco carcinogens and aromatic amines directly cause mutations through the formation of DNA adducts. In particular, 4-aminobiphenyl-DNA adducts have been confirmed to cause characteristic G→T transversion mutations in TP53 and HRAS of bladder cancer cells. Because of the urine storage function of the bladder, carcinogens come into contact with the urothelium at high concentrations for long periods, which explains the bladder's high susceptibility to urothelial carcinoma.


6. Symptoms

The most characteristic and common symptom of D41 neoplasms of uncertain behavior of the urinary organs is painless hematuria. Hematuria presents as gross hematuria or as microscopic hematuria detected only on urinalysis. Even a single episode of gross hematuria is a strong indication for cystoscopic evaluation, and about 80% of patients with bladder tumors are discovered this way. Hematuria occurs intermittently, repeatedly resolving spontaneously and recurring, so patients often overlook it as a transient phenomenon.

Bladder CIS is often accompanied by bladder irritation symptoms. Frequency, urgency, and dysuria characteristically appear, mimicking cystitis. Persistent bladder irritation symptoms that do not respond to antibiotic treatment are a clue suggesting CIS. Upper urinary tract (renal pelvis, ureter) lesions may cause flank pain and unilateral hematuria, and severe flank pain occurs when hydronephrosis develops due to ureteral obstruction. In advanced bladder cancer, lower extremity edema (lymph node metastasis or venous compression), bone pain (bone metastasis), weight loss, and general weakness appear.


7. Signs

In early noninvasive bladder tumors, physical examination findings are usually normal or nonspecific. Cystoscopy is the most important diagnostic means of observation; papillary tumors are seen as papillary masses protruding from the bladder mucosa. CIS appears as red velvety or hyperemic flat lesions of the bladder mucosa and is often difficult to distinguish visually from simple cystitis. On HAL (hexaminolevulinate) fluorescence cystoscopy, CIS shows red fluorescence under blue light and can be detected with much higher sensitivity than with white-light cystoscopy.

On lower abdominal palpation, bladder tenderness or a mass may be palpable when the bladder tumor is large or muscle-invasive. If physical examination reveals lower extremity lymphedema (inguinal or obturator lymph node metastasis), left supraclavicular lymphadenopathy (a sign of distant metastasis of abdominal organ tumors), or dark spots (skin metastasis), an advanced stage is suggested. On renal palpation, renal enlargement due to hydronephrosis may be felt. On digital rectal examination or, in women, bimanual abdominovaginal examination, thickening or induration of the bladder wall may be found when the bladder tumor has invaded the muscle layer.


8. Screening

Systematic screening for early detection of bladder cancer in the general population is currently not officially recommended in any country due to insufficient cost-effectiveness evidence. However, targeted surveillance of high-risk groups is clinically important.

In occupational health programs for high-risk occupational groups (workers exposed to aromatic amines and polycyclic aromatic hydrocarbons), regular urine cytology and cystoscopy are recommended. Urine cytology has high sensitivity for high-grade tumors and CIS (75–95%), but low sensitivity for low-grade papillary tumors (20–40%), so it is insufficient as a stand-alone screening test. Molecular urine markers (NMP22, BTA stat, UroVysion FISH) are being studied to complement urine cytology.

Microscopic hematuria (3 or more red blood cells/HPF on urinalysis) is an important clue in screening for bladder tumors. The Korean Urological Association recommends upper urinary tract imaging and cystoscopic evaluation in men aged 35 or older with microscopic hematuria or women with high-risk factors. Carriers of Lynch syndrome have a high risk of upper urinary tract urothelial tumors and need periodic urologic follow-up.


9. Diagnosis

Confirmation of D41 urinary organ neoplasms relies on histopathological examination, and several imaging and testing tools are used for early detection and staging.

Cystoscopy is the core tool for diagnosing bladder tumors. Flexible cystoscopy can be performed in the outpatient setting under local anesthesia and visualizes the entire bladder mucosa. When abnormal findings are found, the tumor is resected by transurethral resection of bladder tumor (TURBT) to obtain tissue while simultaneously performing therapeutic resection. HAL fluorescence cystoscopy (photodynamic diagnosis) improves CIS detection sensitivity by about 20–25% compared with white-light cystoscopy and contributes to reduced recurrence rates. Narrow band imaging (NBI) also increases lesion detection rates by visualizing vascular patterns.

CT urography (CTU) is the best imaging method for evaluating the entire urinary tract, including the renal pelvis, ureters, and bladder, at once. It allows comprehensive evaluation including upper urinary tract lesions, multifocal lesions, and renal abnormalities. Urine cytology is the core of noninvasive surveillance, with the advantage of high specificity for high-grade lesions and CIS. UroVysion FISH detects numerical abnormalities of chromosomes 3, 7, and 17 and 9p21 loss with fluorescent probes; it is more sensitive than urine cytology and is used as a complement, especially in follow-up of low-grade tumors.


10. Treatment

The primary treatment of noninvasive bladder tumors (D41.4) is transurethral resection of bladder tumor (TURBT). TURBT plays a dual diagnostic and therapeutic role, completely resecting the tumor while obtaining tissue to determine grade and stage. For high-grade or large tumors, repeat resection (re-TURBT) is performed after 2–6 weeks to check for residual tumor and muscle layer invasion. A single immediate postoperative intravesical chemotherapy instillation (MMC or EPI) after TURBT prevents tumor cell implantation and reduces the recurrence rate by about 14%.

Adjuvant intravesical therapy according to recurrence risk is central. In intermediate- and high-risk non-muscle-invasive bladder cancer, intravesical BCG (Bacillus Calmette-Guérin) immunotherapy is standard. BCG reduces the recurrence rate by about 30–40% and suppresses invasive progression through immune-mediated antitumor mechanisms. Induction therapy (once weekly for 6 weeks) followed by maintenance therapy (periodic instillations for 3 years) is recommended. For BCG-unresponsive or recurrent high-risk non-muscle-invasive bladder cancer, pembrolizumab (PD-1 inhibitor) recently received FDA approval as an intravesical treatment alternative (KEYNOTE-676 study). In muscle-invasive bladder cancer, radical cystectomy with urinary diversion is standard, and cisplatin-based neoadjuvant chemotherapy given before surgery improves survival.


11. Prognosis

The prognosis of D41 urinary organ neoplasms varies with tumor grade, stage, presence of concomitant CIS, and BCG responsiveness. The 5-year recurrence rate of PUNLMP is about 35–47%, but progression to muscle-invasive disease is extremely rare (about 0–3%), so the prognosis is very favorable. Low-grade noninvasive papillary urothelial carcinoma (Ta LG) has a 5-year recurrence rate of about 50–70% and a muscle-invasive progression rate of less than about 5%. In high-grade noninvasive papillary urothelial carcinoma (Ta HG), the 5-year recurrence rate is about 50–70% and the 5-year muscle-invasive progression rate is much higher, at about 15–40%.

Bladder CIS is non-muscle-invasive on its own but carries a high risk of progressing to invasive cancer in about 40–80% if untreated. The complete response rate of CIS after BCG treatment is about 70–75%, and the prognosis of BCG-unresponsive CIS is poor without radical cystectomy. The EORTC risk score and the CUETO risk model are used to predict the risk of recurrence and progression. Upper urinary tract urothelial tumors (D41.1, D41.2) tend to be more aggressive than bladder tumors, are mostly diagnosed as advanced or high-grade, and have a 5-year survival of around 50–60%.


12. Prevention

Smoking cessation is the single most effective measure for preventing urothelial tumors of the bladder and upper urinary tract. About 50–65% of bladder cancer cases are estimated to be attributable to smoking, so if smoking cessation were widely achieved, more than half of bladder cancer cases could be prevented. The earlier smoking cessation begins, the greater the risk reduction, and even 20 years after quitting, the risk due to a past smoking history does not completely disappear.

Blocking occupational carcinogen exposure is central to secondary prevention. In work environments where aromatic amine exposure is a concern, wearing personal protective equipment, environmental monitoring, and the use of substitute chemicals for carcinogens should be mandatory. Some developed countries recognize occupational bladder cancer as an industrial accident and operate compensation systems for affected workers. Research results on whether adequate fluid intake lowers bladder cancer risk are somewhat mixed, but there is a theoretical rationale that diluting urine reduces the concentration and duration of contact of carcinogens with the bladder epithelium.

Systematic cystoscopic surveillance is essential to prevent recurrence after treatment of urinary organ neoplasms. For low-risk tumors, cystoscopy is recommended at 3 months and 12 months after TURBT and annually thereafter, while high-risk tumors require more frequent follow-up. Intravesical BCG or MMC maintenance therapy contributes to preventing recurrence. In Lynch syndrome carriers, early detection of upper urinary tract tumors through appropriate genetic counseling and regular urologic checkups is also an important preventive measure.


13. References

  1. Babjuk M, Burger M, Comperat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ). Eur Urol. 2022;81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. PMID: 34511303.

  2. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients. Eur Urol. 2006;49(3):466-477. DOI: 10.1016/j.eururo.2005.12.031. PMID: 16442208.

  3. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25-41. DOI: 10.1038/nrc3817. PMID: 25533674.

  4. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-241. DOI: 10.1016/j.eururo.2012.07.033. PMID: 22877502.

  5. Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. PMID: 27345655.

  6. Alfred Witjes J, Lebret T, Comperat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71(3):462-475. DOI: 10.1016/j.eururo.2016.06.020. PMID: 27375033.

  7. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129. DOI: 10.1016/S0022-5347(05)67707-5. PMID: 10737480.

  8. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195-2203. DOI: 10.1016/j.juro.2009.07.016. PMID: 19758659.

  9. Flaig TW, Spiess PE, Agarwal N, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041-1053. DOI: 10.6004/jnccn.2018.0072. PMID: 30181419.

  10. Galsky MD, Arija JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557. DOI: 10.1016/S0140-6736(20)30230-0. PMID: 32416780.